Mission

Mission

We apply our in-depth experience and expertise in drug and device development to help our clients guide their compounds and devices toward regulatory approval.

InClinica is a global company that specializes in leading companies through early development and on to clinical trials. The company originated in 2007, and was subsequently acquired by Velocity Fund Partners, a private equity firm focused on promising opportunities in life sciences and healthcare services.

Each person in our senior management team has more 30 years of drug and device development experience.

We have experience in multiple diseases and device technologies, conducted across all stages of development, in North America, Asia/Pacific, Europe and Latin America.